Breakthroughs that
change patients’ lives

We reached an estimated 1.4 billion patients with our medicines and vaccines. That’s more than one out of every six people on Earth.

We were able to produce 3 billion doses of the Pfizer-BioNTech COVID-19 vaccine in 2021. (And we expect we can manufacture up to 4 billion doses in 2022).

Influenza results in approximately five million cases of severe illness and up to 650,000 annual deaths worldwide. Current seasonal flu vaccines prevent only 40% to 60% of the disease in the best-matched seasons. We believe mRNA technology has the potential to improve this situation. The swift delivery of the world’s first mRNA-based vaccine for COVID-19 demonstrates mRNA’s viability as a flexible technology and we believe it has the potential to prevent or treat other diseases, including influenza, subject to regulatory approval.

We have pledged 2 billion doses of our COVID-19 vaccine to low- and middle-income countries over 2 years, via government supply agreements, COVAX, government partners’ donation programs, and humanitarian assistance. In 2021, we achieved the first 1 billion doses and we are on track to surpass our 1 billion dose target in 2022.

More than 340 patient advocacy groups and 38,000 Pfizer colleagues participated in Pfizer's first-ever Patients in Focus, a week-long activation of our focus on the patient perspective to build Pfizer’s understanding of the needs of all patients, bring colleagues together to discuss the patient-centric design, and showcase impactful patient advocacy efforts across the company.

Digital is helping us unleash the power of our people — driving innovation, scaling new ways of working and helping colleagues grow their skill sets and access learning opportunities. For example, in finance and operations, we deployed more than 300 bots that reconcile data, create and distribute reports, and proactively identify errors.

Wilson disease may be a rare genetic disorder, but its impact can be substantial. Found in approximately one in 30,000 people worldwide, Wilson disease is caused by a mutation on a single gene, leading to excessive and potentially life-threatening build-up of copper in parts of the body. Currently, the condition can only be cured by liver transplant, but our new gene therapy partnership aiming to address the underlying cause may offer promise to patients and their families.

Addressing and overcoming health care inequities around the world is a top priority for Pfizer. These inequities are most apparent in low- and middle-income countries where, historically, access to effective therapies has been difficult, if not impossible. Through our ongoing collaboration with the IDA Foundation, we’re looking to change that and improve access to life-impacting treatments for more than 27 types of cancer.

In early 2021, we launched a Breakthrough Fellowship Program – a nine-year commitment to increase minority representation and enhance our pipeline of diverse leaders. A first of its kind program, it works to advance students and early career colleagues of Black/African American, Latinx/Hispanic and Native American descent with a goal of developing 100 Fellows by 2025. Our first cohort of 20 rising senior undergraduates completed the first phase of the program, a 10-week internship, in 2021.

Together with Myovant Sciences we celebrated the United States Food and Drug Administration approval of Myfembree®, a once-daily oral treatment offering relief to the estimated five million women in the U.S. suffering from symptoms caused by uterine fibroids – noncancerous tumors that develop in or on the muscular walls of the uterus.